LOH at 1p31 (ARHI) and proliferation in lymph node-negative breast cancer

Cellular Oncology

Volumn 31, Issue 5, 2009, Pages 335-343

  Janssen, Emiel A M ^c   Øvestad, Irene T ^a,c   Skaland, Ivar ^a,c   Søiland, Hâvard ^a,c   Gudlaugsson, Einar ^a,c   Kjellevold, Kjell H ^c   Nysted, Arne ^c   Søreide, Jon Arne ^b,c   Baak, Jan P A ^a,b,c  

^a UNIVERSITY OF BERGEN   (Norway)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

Author keywords

ARHI; Breast cancer; Loss of heterozygosity; PPH3; Proliferation

Indexed keywords

CYCLIN D1; CYCLIN E; HISTONE H3; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P21;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CHROMOSOME 1P; DINUCLEOTIDE REPEAT; DISTANT METASTASIS; ENZYME PHOSPHORYLATION; FEMALE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MITOSIS RATE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL PROLIFERATION; CHROMOSOMES, HUMAN, PAIR 1; FEMALE; HISTONES; HUMANS; LOSS OF HETEROZYGOSITY; LYMPHATIC METASTASIS; MIDDLE AGED; PHOSPHORYLATION; PROGNOSIS; RHO GTP-BINDING PROTEINS; SURVIVAL RATE;

EID: 70149089925     PISSN: 15705870     EISSN: None     Source Type: Journal    
DOI: 10.3233/CLO-2009-0479     Document Type: Article

References (27)

1. J.P. Baak, P.J. van Diest, F.J. Voorhorst et al., Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years, J. Clin. Oncol. 23 (2005), 5993-6001.
2. J.P. Baak, P.J. van Diest, F.J. Voorhorst, other collaborators of the Multicenter Morphometric Mammary Carcinoma Project (MMMCP) et al., The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent, Eur. J. Cancer 43(3) (2007), 527-535.
3. J.P.A. Baak, P.J. van Diest, A. Ariens et al., The multicenter morphometric mammary carcinoma project (MMMCP). A nationwide prospective study on reproducibility and prognostic power of routine quantitative assessments in The Netherlands, Pathol. Res. Pract. 185 (1989), 664-670.
4. [4] J.P.A. Baak, H. van Dop, P.H.J. Kurver et al., The value of morphometry to classic prognosticators in breast cancer, Cancer 56 (1985), 374-382. (Pubitemid 15031663)
5. [5] E. Bergers, J.P. Baak, P.J. van Diest et al., Prognostic implications of different cell cycle analysis models of flow cytometric DNA histograms of 1301 breast cancer patients: results from the Multicenter Morphometric Mammary Carcinoma Project, Int. J. Cancer 74 (1997), 260-269. (Pubitemid 27321793)
6. E. Bergers, P.J. van Diest and J.P.A. Baak, Cell cycle analysis of 932 flow cytometric DNA histograms of fresh frozen breast carcinoma material. Correlations between flow cytometric, clinical and pathologic variables. MMMCP Collaborative Group, Cancern (1996), 2258-2266.
7. R.M. Brenner, O.D. Slayden, W.H. Rodgers et al., Immunohistochemical assessment of mitotic activity with an antibody to phosphorylated histone P.PH3 in the macaque and human endometrium, Hum. Reprod. 18 (2003), 1185-1193.
8. M.G. Daidone and R. Silvestrini, Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer, J. Natl. Cancer Inst. Monogr. 30 (2001), 27-35.
9. I.O. Ellis, S.J. Schnitt, X. Sastre-Garau et al., Invasive breast carcinoma, in: Pathology and Genetics of Tumors of the Breast and Female Genital Tract Organs, F.A. Tavassoli and P. Devilee, eds, IARC Press, Lyon, 2003, pp. 18-19.
10. W. Elston and I.O. Ellis, Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology 19 (1991), 403-410.
11. W. Feng, Z. Lu, R.Z. Luo et al., Multiple histone deacetylases repress tumor suppressor gene ARHI in breast cancer, Int. J. Cancer 120(8) (2007), 1664-1668.
12. M.J. Hendzel, Y. Wei, M.A. Mancini et al., Mitosisspecific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 phase and spreads in an ordered fashion coincident with mitotic chromosome condensation, Chromosoma 106 (1997), 348-360.
13. H. Hisatomi, K. Nagao, K. Wakita et al., ARHI/NOEY2 inactivation may be important in breast tumour pathogenesis, Oncology 62 (2002), 136-140.
14. E.A.M. Janssen, J.P.A. Baak, M.A. Guervós et al., In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor, J. Pathol. 201 (2003), 555-561.
15. [15] E.A.M. Janssen, P.J. van Diest, H. Søiland et al., Success factors of adjuvant chemotherapy in node-negative breast cancer patients under 55 years, Cellular Oncology 28 (2006), 295-303. (Pubitemid 44950100)
16. G. Juan, F. Traganos and Z. Darzynkiewicz, Histone PPH3 phosphorylation in human monocytes and during HL-60 cell differentiation, Exp. Cell Res. 246 (1999), 212-220.
17. G. Juan, F. Traganos, W.M. James et al., Histone PPH3 phosphorylation and expression of cyclins A and B1 measured in individual cells during their progression through G2 and mitosis, Cytometry 32 (1998), 71-77.
18. H. Peng, F. Xu, R. Pershad et al., ARHI is the center of allelic deletion on chromosome 1p31 in ovarian and breast cancers, Int. J. Cancer 86 (2000), 690-694.
19. D.G. Rosen, L. Wang, A.N. Jain et al., Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21 WAF1/CIP1 and prolonged progression-free survival, Clin. Cancer Res. 10 (2004), 6559-6566.
20. R. Silvestrini, M.G. Daidone, G. di Fronzo et al., Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer, Breast Cancer Res. Treat. 7 (1986), 161-169.
21. I. Skaland, E.A. Janssen, E. Gudlaugsson et al., Phosphohistone H3 expression has much stronger prognostic value than classical prognosticates in invasive lymph node-negative breast cancer patients less than 55 years of age, Mod. Pathol. 20(12) (2007), 1307-1315.
22. F.A. Tavassoli and P. Devilee, World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital, Organs, IARC Press, Lyon, 2003, pp. 9-112.
23. P.J. van Diest, J.P.A. Baak, P. Matze-Cok et al., Reproducibility of mitosis counting in 2469 breast cancer specimens: results from, the multicenter morphometric mammary carcinoma project, Hum. Pathol. 23 (1992), 603-607.
24. [24] P.J. van Diest, E. van der Wall and J.P. Baak, Prognostic value of proliferation in invasive breast cancer: a review, J. Clin. Pathol. 57 (2004), 675-681. (Pubitemid 38901478)
25. [25] Y. Yu, S. Fujii, J. Yuan et al., Epigenetic regulation of ARHI in breast and ovarian cancer cells, Ann. N.Y. Acad Sci. 983 (2003), 268-277. (Pubitemid 36399339)
26. Y. Yu, R. Luo, Z. Lu et al., Biochemistry and biology of ARHI (DIRAS 3), an imprinted tumor suppressor gene whose expression is lost in ovarian and breast cancers, Methods Enzymol. 407 (2005), 455-468.
27. Y. Yu, R Xu, H. Peng et al., NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas, Proc. Natl. Acad. Sci. USA 96 (1999), 214-219.